Harvard Business School has launched a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.
The Health Care Initiative at Harvard Business School (HBS) has launched the Precision Trials Challenge (www.precisiontrialschallenge.org), a competition to generate ideas to bring precision diagnostics and therapies to market more quickly by reinventing the clinical trials process.
The challenge is open to all and will accept applications at (www.precisiontrialschallenge.org until March 13, 2016. A panel of judges will select one winner and two runners-up to share a $100,000 prize. The winner will be announced in April and have the opportunity to present at the prestigious 2016 Personalized Medicine Conference.
“Advancements in science and technology in the past ten years have led to great advances in precision medicine,” said HBS professor Richard Hamermesh. “However, many of the big challenges facing precision medicine today are actually business challenges. How can we develop business models that support the advancement of precision medicine? How can we get new therapies to market faster and at a lower cost? Our Precision Trials Challenge will help answer these questions by encouraging conversation and helping to put leading-edge ideas into practice.”
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.